Latest Headlines

Latest Headlines

Trial set for Pfizer in Protonix Medicaid rebate case it inherited

A federal judge's inclination means Pfizer could remain in the line of fire to pay out more than $2 billion. That is the potential liability Pfizer faces for a federal lawsuit accusing its Wyeth unit of failing to pay Medicaid rebates for stomach upset drug Protonix.

UPDATED: J&J-Bayer and Pfizer-BMS look for marketing advantages in real-world Xarelto, Eliquis data

Johnson & Johnson and Bayer are leading the four-horse race among new-age anticoagulants, and they're hoping some new real-world safety data for Xarelto can help keep the med in the No. 1 spot.

Japan's MHLW gives nods for Remicade, VFend, Tracleer, INOflo new indications

Japan's Ministry of Health, Labor and Welfare last week gave the nod to several new drug indications, including Mitsubishi Tanabe's Remicade for intravenous use and indications of entero-Behcet, neuro-Behcet and vasculo-Behcet diseases when existing treatments are inadequate, a spokesman for the ministry said.

Patient education 'useless' when it comes to Eliquis adherence: study

Good news for partners Bristol-Myers Squibb and Pfizer: In a Phase IV study of their new-age anticoagulant, Eliquis, atrial fibrillation patients posted adherence rates near 90%. And the icing on the cake? The company didn't need to shell out on patient education to get them there.

China slaps Pfizer with $500,000 in Viagra penalties for pharmacy tie-up

Pfizer has no problem keeping sales for Viagra flying high in China, where brand awareness campaigns and changing attitudes toward sex have given it a sizable hold on the ED market. But the company is facing some headwind in the country, as Chinese marketing authorities slapped Pfizer with a fine for paying local drugstores to promote its blockbuster ED med.

Pfizer plots Ibrance expansion as early-stage breast cancer trial begins

Pfizer's new breast-cancer-fighter, Ibrance, has gotten off to a quick start in patients with advanced breast cancer. And now, the company is embarking on a study to see whether it can work earlier in the disease, too.

Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials

Pfizer's meningitis B vaccine Trumenba won the FDA's blessing nearly a year ago based on impressive midstage results and a national unease about the infection spreading on college campuses. Now, just in time for the back to school season, the New York-based pharma on Friday announced positive late-stage results in nearly 7,000 individuals that confirmed the vaccine's effectiveness against certain meningits B strains.

Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partners

Who should serial buyer Allergan pick up next? It's the question on the minds of many industry watchers--including Evercore ISI analyst Umer Raffat, who polled investors last week. And while there are lots of possibilities floating around, his respondents seem to have a pair of potential deals in mind.

Analyst: Pfizer may favor Hospira's Remsima over in-house Remicade biosim

When Pfizer agreed to shell out $15 billion-plus for Hospira earlier this year, the pharma giant added major heft to its biosimilars pipeline. At the time, CEO Ian Read said the two companies had "complementary" portfolios of biosimilar prospects--and his tune hasn't changed since.

Pfizer to cover NHS docs' script-switching costs in latest Lyrica-protecting move

Pfizer plans to pay doctors in England to prescribe its drug Lyrica. But don't jump to conclusions. These payments are in a category all their own.